# Therapeutic in vivo delivery of gene editing agents

Review · Raguram A, Banskota S, Liu DR

- Archive id: doi:10.1016/j.cell.2022.03.045
- Published: 2022-07-06
- Venue: Cell
- DOI: https://doi.org/10.1016/j.cell.2022.03.045
- PMID: 35798006
- PMCID: PMC9454337
- Citations: 459
- Source URL: https://doi.org/10.1016/j.cell.2022.03.045
- PDF: https://europepmc.org/articles/PMC9454337/pdf
- Provenance: europepmc

## Abstract

In vivo gene editing therapies offer the potential to treat the root causes of many genetic diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to safely and efficiently deliver gene editing agents to relevant organs and tissues in vivo. Here, we review current delivery technologies that have been used to enable therapeutic in vivo gene editing, including viral vectors, lipid nanoparticles, and virus-like particles. Since no single delivery modality is likely to be appropriate for every possible application, we compare the benefits and drawbacks of each method and highlight opportunities for future improvements.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.